Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > In the spirit of anti-virals ... Pfizer acquisition
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Post by MrMugsyon Jun 26, 2022 11:48pm
351 Views
Post# 34783717

In the spirit of anti-virals ... Pfizer acquisition

In the spirit of anti-virals ... Pfizer acquisitionIn the spirit of ATB-344, here's one in a line of growing valuations for pharma acquisitions ...

2 Phase 2 products for RSV - specialized anti-viral for elderly and children.
1 Phase 1 product for RSV for both elderly and children.
1 combination product in pre-clinical.

Global market size seems to be around $2B and growing.
Expected market size is $4.2B by 2027.

Small compared to OTENA's market size.

See what you think.

Pfizer Acquires ReViral for $525M, Renews Pharma Acquisition Spree

June 23, 2022 - Pfizer has announced or completed the acquisition of four pharmaceutical companies in the past year. The most recent of which incorporated ReViral Ltd, adding another antiviral drugmaker to Pfizer’s roster. ReViral specializes in treating respiratory syncytial virus (RSV) — an infectious disease primarily affecting babies and the elderly.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities